Close

IMGN Financial Facts

Clinical materials reimbursement: 46K
Research and development support: 1.35M
See Full Income Statement

Accrued compensation: 6.75M
Other assets: 3.13M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 4/25/24 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +73.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +51.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/12/21 Q420 $0.16-$0.10 +$0.26$85.8M$37.09M = Details
11/1/19 Q319 -$0.15-$0.18 +$0.03$13.28M$9.88M = Details
2/14/20 Q419 $0.03-$0.05 +$0.08$44.9M$29.33M = Details
4/28/23 Q123 -$0.16-$0.25 +$0.09$49.9M$20.97M N/A Details
1/30/15 Q215 $0.16-$0.05 +$0.21$48.3M$37.3M N/A Details
5/3/19 Q119 -$0.30-$0.20 -$0.10$8.6M$10.59M = Details
7/28/17 Q217 -$0.10-$0.17 +$0.07$39.02M$30.6M = Details
2/8/19 Q418 -$0.28-$0.32 +$0.04$13.8M$12.27M = Details